Insect-derived growth factor (IDGF) was originally isolated from conditioned medium of NIH-Sape-4 cells derived from flesh fly embryos. Here we demonstrated that IDGF has adenosine deaminase activity. The substrate specificity of IDGF was similar to that of the mammalian cytoplasmic adenosine deaminase. The adenosine deaminase activity of IDGF was shown to be indispensable for its growth factor activity toward NIHSape-4 cells. We found that there are specific binding sites for IDGF on the surface of NIH-Sape-4 cells and that it binds to these sites with a K d value of 2.4 ؋ 10 ؊10
Growth factors that regulate cell proliferation and differentiation are widely distributed in both vertebrate and invertebrate species (1) (2) (3) . Growth factors are known to bind to specific receptors on the cell surface, causing conformational changes of the receptors enabling them to transmit specific signals for cell growth (4 -6) . The conformational changes of the receptors induced by ligand binding are considered to be the first critical step for the subsequent sequential reactions that take place in the cells.
In invertebrates, especially in insects, several growth factors with vertebrate homologues have been assigned at the gene or cDNA level (7) (8) (9) , but few vertebrate growth factors homologous to invertebrate ones have been substantially identified.
Insect-derived growth factor (IDGF) 1 is a novel soluble growth factor that was purified from conditioned medium of NIH-Sape-4, an embryonic cell line of Sarcophaga peregrina (flesh fly), and then characterized (10) . It consists of 553 amino acid residues and stimulates the growth of NIH-Sape-4 cells at concentrations of 0.7-5 ng/ml, its specific activity being comparable with that of mammalian growth factors. IDGF exhibits no significant sequence similarity with any other growth factors so far characterized but shows about 25% sequence identity with the atrial gland granule-specific antigen of Aplysia californica, which is a secretory protein of unknown function (11) . Although IDGF is assumed to play a role in the proliferation of Sarcophaga embryonic cells, its mode of action remains to be elucidated.
Meanwhile, a number of genes structurally related to that of IDGF have been registered in data bases, suggesting that IDGF is a member of a protein family widely distributed in the animal kingdom. Recently, three products of IDGF family protein genes were characterized. One is a novel Drosophila gene, MSI (male-specific IDGF), of which the product is expressed exclusively in the membranes of mature spermatocytes in the adult testis, suggesting that MSI plays a role in spermatogenesis. When MSI was exogenously expressed in Schneider's line 2 cells, it was shown to be localized on the cell surface and to exhibit growth factor activity via cell to cell interaction, indicating that MSI is a transmembrane extracellular signaling molecule (12) . Other insect IDGF family genes (i.e. TSGF-1 and TSGF-2 (Glossina morsitans salivary gland growth factor genes)) have also been reported, their transcripts being preferentially localized in the salivary glands (13) .
A human IDGF family gene, cat eye syndrome critical region gene 1 (CECR1), is expressed in many adult tissues and in the embryonic outflow tract and atrium of the developing heart, the VII/VIII cranial nerve ganglion, and the notochord (14) . From the chromosomal location and embryonic expression of CECR1, this gene was suggested to be responsible for cat eye syndrome, which involves developmental disorders of multiple organs accompanying duplication of a 2-megabase pair region of 22q11.2 (15, 16) . It has been pointed out that the adenosine deaminase (ADA) domain is structurally conserved in the carboxyl-terminal region of CECR1 (14) .
In this paper, we report that IDGF exhibits ADA activity and that this activity is indispensable for its growth factor activity toward NIH-Sape-4 cells.
EXPERIMENTAL PROCEDURES
Cells and Animals-NIH-Sape-4 cells were cultured in M-M medium (17) at 25°C, as described previously (18) . Flesh flies, S. peregrina, were reared by the method of Ohtaki (19) . The flesh fly is an ovoviviparous insect, so unfertilized eggs and embryos were collected from adult uteri as described previously (20) . Embryos from 6-day-old flies are at the cellular blastodermal stage, and 11-day-old flies oviposit the first instar larvae. Adults are imaged 10 days after pupation.
Assay of Growth Factor Activity-This was carried out as described previously by assessing the stimulation of cell proliferation (10) . Briefly, NIH-Sape-4 cells were suspended at a density of 2.5 ϫ 10 5 cells/ml in M-M medium containing streptomycin (0.5 mg/ml) and penicillin G (120 units/ml), and then 100 l of the cell suspension was poured into each well of a 96-well microtiter plate. The cell numbers did not increase appreciably, even when cultured for 7 days at 25°C under these conditions, because the initial cell density was low. However, a significant increase in cell proliferation was detected when 100 pg of purified IDGF was added to the wells. Cell proliferation was determined by measurement of the enhancement of cellular metabolism by means of the Alamar Blue assay (21, 22) . The cells were incubated for 2 days at 25°C in the presence or absence of the test samples. Then 15 l of Alamar Blue (Alamar Biosciences, Inc.) was added, and then changes in the color of the culture medium were monitored by measuring A 570 and A 610. In this assay, the reducing activity generated by proliferating cells changed the color of the Alamar Blue. One unit of growth factor was defined as the amount giving half-maximal stimulation of cell proliferation.
Preparation of a Recombinant IDGF-The coding region of IDGF cDNA was amplified by PCR with specific primers under the following conditions: 30 cycles each comprising 94°C for 0.5 min, 45°C for 0.5 min, and 72°C for 2 min. The primers used were 5Ј-TTTCATATGGC-AAATCACATGGTACAACAT-3Ј (sense) and 5Ј-GGCAAGCTTCGCGG-CGAACAGGAGGTGTGC-3Ј (antisense). For ligation to the expression vector, the sense primer contained the first Met codon and an NdeI site, and the antisense primer contained the termination codon and a Hind-III site. The resulting PCR product (1.6 kilobase pairs) extracted from the agarose gel was ligated to expression vector pET 17b and then amplified in Escherichia coli JM109. The resulting plasmid was transfected into E. coli BL21, and then the recombinant IDGF was expressed by culturing the bacteria in LB medium containing 0.4 mM isopropyl-1-thio-␤-D-galactoside. The E. coli cells were collected by centrifugation, disrupted in buffer I (10 mM sodium phosphate buffer (pH 6.8)) by sonication, and centrifuged at 10,000 ϫ g for 30 min, and then saturated (NH 4 ) 2 SO 4 was added to the resulting supernatant to a final concentration of 30% (v/v). Purification of the recombinant IDGF was performed essentially as described previously (10) . The protein concentration was determined by the method of Lowry et al. (23) with bovine serum albumin as the standard.
Site-directed Mutagenesis-The point mutations of D462E, D462N, H405E, and H405R were introduced by PCR using Pfu polymerase (Stratagene) (24) . The two terminal primers were F (GGG AAT TCC ATA TGG CAA ATC ACA TGG TAC AAC AT) for the 5Ј end and R (CCC AAG CTT TCA AAT GAT TTT ATT CGT ATT) for the 3Ј-end. The point mutations of D462E, D462N, H405E, and H405R were introduced with primers D462E.D1 (GAA AGA AGG ATC C TCG GAG GAT ATA ACC ACA GGA TAA) and D462E.D2 (TAT ATC CTC CGA G GAT CCT TCT TTC TGG AAA GCT ACA), D462N.D1 (AAG AAG GAT CAT T GGA GGA TAT AAC CAC AGG ATA ATT) and D462N.D2 (GTT ATA TCC TCC A ATG ATC CTT CTT TCT GGA AAG CTA), H405E.D1 (CAA AGC AAA ACC CTC GCC TAT GCG CTT AGT GCC CAA TAA) and H405E.D2 (AAG CGC ATA GGC GAG GGT TTT GCT TTG GTC AAA CAT CCA), and H405R.D1 (AAA GCA AAA CCA C GGC CTA TGC GCT TAG TGC CCA ATA) and H405R.D2 (AGC GCA TAG GCT G CGG TTT TGC TTT GGT CAA ACA TCC), which were combined with F and R, respectively, to generate 5Ј and 3Ј fragments. These fragments were fused by annealing their overlapping ends and amplified with primers F and R to give the final PCR products. The PCR products digested with NdeI and HindIII were cloned into vector pET 17b (Novagen) using a DNA Ligation Kit version 2 (TaKaRa, Tokyo, Japan), and the correctness of the sequences was confirmed with a Dye Terminator Cycle Sequencing Ready Reaction Kit (ABI).
Assay of the ADA Activity of IDGF-The ADA activity of IDGF was assayed by measuring the rate of the ADA-dependent increase in inosine absorption at 235 nm with 25-200 mol of adenosine as the substrate (25) . One unit of ADA activity was defined as the amount of enzyme that produced 1 mol of inosine/min. The assay was carried out in 50 mM potassium phosphate buffer, pH 7.2, using a cuvette of 1-cm path length at 25°C. Activity was measured with four different concentrations of adenosine or an alternative substrate, and the assay was repeated at least twice. The concentrations of adenosine and alternative substrates were 25, 50, 100, and 200 M. The concentration of IDGF in the assay mixture ranged from 0.16 to 1 M. Kinetic parameters K m and V max were determined by means of Lineweaver-Burk plots. k cat was calculated with the equation,
Binding Assay for IDGF-IDGF was radioiodinated by the method of Hunter and Greenwood (26) . The specific activity of labeled IDGF was usually 10 7 cpm/g of protein.
The radioreceptor assay was based on the method of Smith and Cantrell (27) . NIH-Sape-4 cells (5 ϫ 10 5 /0.2 ml) were placed in siliconized tubes with serially diluted 125 I-labeled IDGF (1-500 pM) in M-M medium. The cells were then incubated at 4°C for 2 h with occasional shaking to keep the cells in suspension. Then 1 ml of ice-cold M-M medium was added, and the cells were spun down (9000 ϫ g for 15 s). The supernatant was removed, and its radioactivity was measured to determine the concentration of free 125 I-labeled IDGF. The pellet was resuspended in 0.1 ml of ice-cold M-M medium and then washed three times by repeated centrifugation. The resulting pellet was then suspended in 0.1 ml of ice-cold M-M medium, and its radioactivity was measured. Nonspecific binding was determined in the presence of 20 nM unlabeled IDGF. Specific binding was calculated by subtracting nonspecific binding from total binding. The dose-response curve of the binding of IDGF to a fixed number of NIH-Sape-4 cells reached a plateau with an increase in the concentration of 125 I-labeled IDGF. Western Blotting-Western blotting was performed essentially as described by Burnette (28) . Briefly, proteins separated by SDS-polyacrylamide gel electrophoresis were transferred to a polyvinylidene difluoride membrane filter, which was then treated with a 0.5 g/ml anti-IDGF antibody solution followed by peroxidase-linked anti-rabbit donkey IgG diluted 1:5000. The filter was then treated with ECL Western blotting detection reagents (Amersham Pharmacia Biotech) and exposed to x-ray film.
Immunoprecipitation of Phosphotyrosyl Proteins from Cell LysateImmunoprecipitation of phosphotyrosyl proteins was performed as described by Luttrell et al. (29) . NIH-Sape-4 cells (4 ϫ 10 6 /0.4 ml) were incubated for appropriate times in the presence of IDGF (50 ng/ml). Then 0.4 ml of ice-cold extraction buffer (40 mM HEPES, 150 mM NaCl, 30 mM Nonidet P-40, 2 mM Na 3 VO 4 , 4 mM Na 4 P 2 O 7 , 4 mM EDTA, 2 mM phenylmethylsulfonyl fluoride, 4 g/ml aprotinin) was added, sonicated briefly, and kept at 4°C for 30 min with agitation. After centrifugation at 10,000 ϫ g for 20 min, the supernatant was incubated with 20 l of a 1:1 slurry of Sepharose CL-4B (Amersham Pharmacia Biotech) for 30 min at 4°C and centrifuged again at 10,000 ϫ g for 20 min. Then 10 l of anti-phosphotyrosine monoclonal antibody PY20 (0.1 mg/ml) (Chemicon) was added to the supernatant and incubated at 4°C for 90 min with agitation. Then 20 l of a 1:1 slurry of Protein G-Sepharose FF (Amersham Pharmacia Biotech) was added, and incubation was continued for 90 min. The precipitate was collected by centrifugation, washed three times with extraction buffer, dissolved in 1% SDS containing 2% (v/v) 2-mercaptoethanol, and analyzed by Western blotting with 1 g/ml of anti-phosphotyrosine polyclonal antibody 06-427 (Upstate Biotechnology, Inc.).
Northern Blot Hybridization-Total RNA was extracted from flesh flies at various developmental stages by the guanidine-thiocyanate method (30) . RNA (20 g) was separated on a 1.2% (w/v) agarose gel containing formaldehyde and then blotted onto a Gene Screen Plus (PerkinElmer Life Sciences) in 10ϫ SSPE (1ϫ SSPE: 180 mM NaCl, 10 mM NaH 2 PO 4 , 1 mM EDTA, pH 7.4). Hybridization was performed in a 50% (v/v) formamide, 5ϫ SSPE, 1ϫ Denhardt's solution (0.02% (w/v) each of Ficoll-400, bovine serum albumin, and polyvinylpyrrolidone), 0.2 mg/ml single-stranded salmon sperm DNA solution for 16 h at 42°C. The filters were autoradiographed at Ϫ80°C. The DNA used as a probe was a full length of IDGF cDNA. This probe was labeled with [␣-32 P]dCTP using a BcaBEST random primer labeling kit (TaKaRa). The filter was subsequently hybridized with a glyceraldehyde-3-phosphate dehydrogenase cDNA probe to determine the amount of RNA loaded.
Other Methods-The antibody against IDGF was raised as described previously (10) . SDS-polyacrylamide gel electrophoresis was performed by the method of Laemmli (31) . DNA manipulations including sequencing, PCR, plasmid isolation, and E. coli transformation were carried out according to standard methods (32) .
RESULTS

Preparation of Recombinant IDGF-Accumulating
To determine the relationship between the growth factor activity of IDGF and its putative ADA activity, we first examined whether or not IDGF has ADA activity. For this, we produced a recombinant IDGF using an E. coli expression system. The recombinant IDGF was expressed in E. coli only in the presence of isopropyl-1-thio-␤-D-galactoside, and it was purified from an E. coli lysate to homogeneity (Fig. 1A) . As summarized in Table I , about 1 mg of pure recombinant IDGF was obtained from 250 ml of E. coli culture.
The growth factor activity of the recombinant IDGF was compared with that of authentic IDGF. As shown in Fig. 2 , the two proteins showed very similar dose-response relationships, and the specific activity of recombinant IDGF was almost identical to that of the authentic one.
ADA Activity of IDGF Is Essential for Its Growth Factor Activity-As a sufficient quantity of the recombinant IDGF was obtained, we measured its ADA activity. As shown in Table II , the ADA activity of IDGF was clearly detected when adenosine, 2Ј-deoxyadenosine, and 3Ј-deoxyadenosine were used as substrate. The K m , V max , and k cat values obtained with adenosine, 2Ј-deoxyadenosine, and 3Ј-deoxyadenosine were comparable with those of mammalian cytoplasmic ADA (33) . These results indicate that IDGF is in fact an ADA and that IDGF family proteins can be classified into a new ADA group, namely secretory or transmembrane ADAs, since their overall sequences are unique except for in the ADA domain.
To determine the relationship between the growth factor activity and ADA activity of IDGF, we examined the effect of 2Ј-deoxycoformycin (DCF) on the growth factor activity of IDGF. This compound is known to be a potent inhibitor of mammalian ADAs and to inactivate them irreversibly (34) . For measurement of the growth factor activity, we first treated the IDGF with DCF, and then the growth factor activity was determined. The ADA activity of IDGF was assayed in the presence of DCF. As shown in Fig. 3 , both the ADA and growth factor activities decreased in the same way with an increase in the concentration of DCF, and no appreciable activities were detected in the presence of 10 Ϫ7 M DCF. These results strongly suggested that the ADA activity of IDGF is essential for its growth factor activity.
To further confirm these results, we prepared the recombinant IDGF with mutations in its ADA domain. For this, we designed four mutants as to Asp 462 and His 405 , which correspond to Asp 295 and His 238 of mouse cytoplasmic ADA, respectively. In mouse ADA, Asp 295 is known to play a critical role in the deamination of adenosine through interaction with the catalytic water (25) , and His 238 is also known to play a crucial role in the catalytic reaction (35) . These two residues are conserved in many IDGF family proteins. The mutants we constructed were designated as D462E, D462N, H405E, and H405R. The sequence of the synthesized cDNA for each mutant was confirmed.
Expression of each mutant was performed as for the recombinant IDGF, and each mutant was purified to homogeneity, as judged on SDS-polyacrylamide gel electrophoresis and immunoblotting (Fig. 1, B and C) . No appreciable ADA activity was detected with any of these mutants, indicating that both Asp 462 and His 405 are essential residues for the ADA activity of IDGF. The kinetic parameters (K m , V max , and k cat ) of D462E, D462N, H405E, and H405R could not be determined.
Next, the growth factor activity of the mutant proteins was examined. As shown in Fig. 4 , these mutants rather inhibited the growth of NIH-Sape-4 cells, and no significant dose-dependent growth stimulation was detected like that in the case of the wild-type IDGF. From these results, we concluded that the ADA activity of IDGF is linked to its growth factor activity.
We examined whether mammalian ADA has growth factor activity on NIH-Sape-4 cells, and found that commercially available calf spleen ADA stimulated their growth in a dosedependent manner. However, its growth factor activity could not be compared directly with that of IDGF because of its low purity.
Binding of IDGF to NIH-Sape-4 Cells-Since the ADA activity of IDGF was shown to be indispensable for its growth factor activity, there remained the possibility that IDGF converts adenosine analogues in the medium into inosine analogues, which stimulate the growth of NIH-Sape-4 cells in some way. Therefore, we added various adenosine analogues and inosine analogues (adenosine, 2Ј-deoxyadenosine, 3Ј-deoxyadenosine, 5Ј-AMP, inosine, 2Ј-deoxyinosine, 3Ј-deoxyinosine, 5Ј-IMP, and arabinofuranosyladenine) to the culture medium of NIHSape-4 cells at a concentration of 1 mM and then examined their growth stimulation effects. However, they caused essentially no growth stimulation of NIH-Sape-4 cells. Therefore, it is assumed that the growth stimulation of NIH-Sape-4 cells by IDGF is not simply due to the production of inosine analogues in the medium.
We examined the effect of anti-IDGF antibody for the proliferation of NIH-Sape-4 cells, but essentially no appreciable inhibitory effect was detected. Possibly, this antibody detects epitopes on IDGF that are not involved in the growth factor activity. To gain more insight into the mechanism underlying the growth stimulation by IDGF, we examined the binding of IDGF to NIH-Sape-4 cells. For this, we prepared radioiodinated IDGF and measured its specific binding to NIH-Sape-4 cells. Scatchard analysis revealed that NIH-Sape-4 cells have one type of binding site for IDGF. Five independent experiments showed that IDGF binds to NIH-Sape-4 cells with a K d value of about 2 ϫ 10 Ϫ10 M, and the number of binding sites was calculated to be in the range of 1500 -10,000/cell. These results suggest that IDGF exerts its growth factor activity by binding to a specific molecule that is present on the cell surface and then transmits a signal for growth into the cells. This molecule may be a substrate for ADA, and deamination of this substrate by IDGF is a prerequisite for transmission of the growth signal into the cells.
So far, we have not succeeded in identifying the IDGF receptor. However, Western blotting using anti-phosphotyrosine antibody revealed that tyrosine phosphorylation of a protein with a molecular mass of 180 kDa was transiently enhanced at 2 min post-stimulation with IDGF (Fig. 5) . In this experiment, we used 50 ng/ml of IDGF, and the result was reproducible. Similar results were obtained with IDGF concentrations of 1 ng/ml and 10 ng/ml. The molecular nature of this protein is Fig. 6 , unfertilized eggs contained a significant amount of maternal mRNA for IDGF, which decreased with development of the embryos, suggesting that the maternal mRNA was translated into IDGF and that the resulting IDGF enhanced the proliferation of embryonic cells during embryogenesis. Another stage at which expression of the IDGF gene was obvious was in first instar larvae. The size of the mRNA produced at this stage was a little smaller, but it contained the complete open reading frame for IDGF, suggesting that IDGF is also needed for larval maturation.
DISCUSSION
The ADA family has previously been classified into two groups. The first group includes cellular enzymes that are involved in purine metabolism and are indispensable for the upkeep of a competent immune system, since genetic defects of them are associated with severe combined immunodeficiency diseases (36) . The second group comprises the double-stranded RNA-specific ADA that contains unique RNA-binding domains. This ADA is assumed to participate in RNA editing of specific mRNA (37) . Since IDGF was found to have ADA activity and since no significant sequence similarity was found between IDGF and known ADAs except for in their ADA domains, the IDGF family proteins may be classified into a third group that comprises secretory or transmembrane ADAs.
We demonstrated that the ADA activity of IDGF is essential for its growth factor activity and suggested the presence of IDGF binding sites on the surface of NIH-Sape-4 cells. This binding site for IDGF is likely to be specific, and once IDGF binds to this receptor, a signal may be transmitted into the cells, resulting in stimulation of their proliferation. ADA activity seems to be implicated in this process. One possibility is that the receptor may be modified with an adenosine moiety, and conversion of this adenosine to inosine by ADA is indispensable for the receptor to transmit the growth signal into the cells.
It has been shown that a specific ADA binding site is present in CD26 (38, 39) , which is a transmembrane dipeptidyl peptidase located on the surface of mammalian lymphocytes (40) . However, nothing is known about the physiological meaning of this ADA binding site. Judging from the present results together, there is a possibility that CD26 is a transmembrane signaling molecule like the putative IDGF receptor. Thus, it may be worthwhile examining whether or not CD26 is modified with an adenosine moiety. The relationship between CD26 and the phosphorylated protein with the molecular mass of 180 kDa in the IDGF signaling pathway is another important issue.
As was evident from Northern blotting, unfertilized eggs contain a significant amount of IDGF mRNA. This suggests that IDGF is needed immediately when embryonic cells are formed after fertilization. It is not clear whether the mRNA detected in embryos at an early developmental stage is a carryover of maternal mRNA or mRNA synthesized in situ. However, the latter possibility is more likely, since NIH-Sape-4 cells originating from Sarcophaga embryos constitutively synthesize IDGF. A significant amount of mRNA was detected in the first instar larvae, suggesting that IDGF is needed for the proliferation of certain larval cells. Clearly, this mRNA is synthesized in situ, because its molecular size is a little smaller than that of the maternal or embryonic mRNA. We confirmed that the smaller mRNA contains the same open reading frame as the maternal or embryonic mRNA. The smaller mRNA is thus likely to be produced through alternative splicing of the precursor RNA, but we have not yet determined the complete sequence of the smaller mRNA.
It is noteworthy that the IDGF family proteins are widely distributed in the animal kingdom. The gene for CECR1 (14) , the human homologue of IDGF, is considered to be one of the most likely genes involved in cat eye syndrome (41, 42) . Analysis of the ADA activity as well as the growth factor activity of CECR1 from patients may provide clues as to this disease. It is known that mammalian serum contains a certain level of adenosine, which functions as a synaptic, angiogenic, and vasculogenic modulator (43) . It is also possible that a humoral protein such as CECR1 participates in the maintenance of the adenosine level in the serum.
An ADA inhibitor, DCF, has been widely used as a chemotherapeutic agent for leukemias such as adult T-cell leukemia (44) and hairy cell leukemia (45) . However, it is known that the permeability of cell membranes to DCF is very low and that it does not penetrate into leukemia cells. Moreover, the toxicity of DCF against leukemia cells was found to be very low when examined in vitro. 2 These facts suggest the possibility that the real target of DCF in leukemia patients is an extracellular ADA like IDGF, not a cytoplasmic ADA. To prove this, more detailed examinations are needed.
